355. Montegut, L.; Abdellatif, M.; Motino, O.; Madeo, F.; Martins, I.; Quesada, V.; Lopez-Otin, C.; Kroemer, G. Acyl coenzyme a binding protein (acbp): An aging- and disease-relevant "autophagy checkpoint". *Aging Cell* **2023**, *22*, e13910. [CrossRef]

356. Joseph, A.; Chen, H.; Anagnostopoulos, G.; Montegut, L.; Lafarge, A.; Motino, O.; Castedo, M.; Maiuri, M.C.; Clement, K.; Terrisse, S.; et al. Effects of acyl-coenzyme a binding protein (acbp)/diazepam-binding inhibitor (dbi) on body mass index. *Cell Death Dis.* **2021**, *12*, 599. [CrossRef]

357. Bravo-San Pedro, J.M.; Sica, V.; Martins, I.; Pol, J.; Loos, F.; Maiuri, M.C.; Durand, S.; Bossut, N.; Aprahamian, F.; Anagnostopoulos, G.; et al. Acyl-coa-binding protein is a lipogenic factor that triggers food intake and obesity. *Cell Metab.* **2019**, *30*, 754-767.e9. [CrossRef]

358. Motino, O.; Lambertucci, F.; Anagnostopoulos, G.; Li, S.; Nah, J.; Castoldi, F.; Senovilla, L.; Montegut, L.; Chen, H.; Durand, S.; et al. Acbp/dbi protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2207344119. [CrossRef]

359. Anagnostopoulos, G.; Saavedra, E.; Lambertucci, F.; Motino, O.; Dimitrov, J.; Roiz-Valle, D.; Quesada, V.; Alvarez-Valadez, K.; Chen, H.; Sauvat, A.; et al. Inhibition of acyl-coa binding protein (acbp) by means of a gaba(a)rgamma2-derived peptide. *Cell Death Dis.* **2024**, *15*, 249. [CrossRef] [PubMed]

360. Anagnostopoulos, G.; Motino, O.; Li, S.; Carbonnier, V.; Chen, H.; Sica, V.; Durand, S.; Bourgin, M.; Aprahamian, F.; Nirmalathasan, N.; et al. An obesogenic feedforward loop involving ppargamma, acyl-coa binding protein and gaba(a) receptor. *Cell Death Dis.* **2022**, *13*, 356. [CrossRef]

361. Duman, C.; Yaqubi, K.; Hoffmann, A.; Acikgoz, A.A.; Korshunov, A.; Bendszus, M.; Herold-Mende, C.; Liu, H.K.; Alfonso, J. Acyl-coa-binding protein drives glioblastoma tumorigenesis by sustaining fatty acid oxidation. *Cell Metab.* **2019**, *30*, 274-289.e5. [CrossRef] [PubMed]

362. Duman, C.; Di Marco, B.; Nevedomskaya, E.; Ulug, B.; Lesche, R.; Christian, S.; Alfonso, J. Targeting fatty acid oxidation via acyl-coa binding protein hinders glioblastoma invasion. *Cell Death Dis.* **2023**, *14*, 296. [CrossRef] [PubMed]

363. Yao, J.; Liu, Y.; Yang, J.; Li, M.; Li, S.; Zhang, B.; Yang, R.; Zhang, Y.; Cui, X.; Feng, C. Single-cell sequencing reveals that dbi is the key gene and potential therapeutic target in quiescent bladder cancer stem cells. *Front. Genet.* **2022**, *13*, 904536. [CrossRef] [PubMed]

364. Jacob, J.B.; Wei, K.C.; Bepler, G.; Reyes, J.D.; Cani, A.; Polin, L.; White, K.; Kim, S.; Viola, N.; McGrath, J.; et al. Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model. *iScience* **2023**, *26*, 106320. [CrossRef] [PubMed]

365. Harris, F.T.; Rahman, S.M.; Hassanein, M.; Qian, J.; Hoeksema, M.D.; Chen, H.; Eisenberg, R.; Chaurand, P.; Caprioli, R.M.; Shiota, M.; et al. Acyl-coenzyme a-binding protein regulates beta-oxidation required for growth and survival of non-small cell lung cancer. *Cancer Prev. Res.* **2014**, *7*, 748-757. [CrossRef] [PubMed]

366. Cavalloni, G.; Peraldo-Neia, C.; Massa, A.; Bergamini, C.; Trentini, A.; De Rosa, G.; Daniele, L.; Ciccosanti, F.; Cervellati, C.; Leone, F.; et al. Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in italian intrahepatic cholangiocarcinoma patients. *BMC Cancer* **2021**, *21*, 865. [CrossRef] [PubMed]

367. Venturini, I.; Zeneroli, M.L.; Corsi, L.; Baraldi, C.; Ferrarese, C.; Pecora, N.; Frigo, M.; Alho, H.; Farina, F.; Baraldi, M. Diazepam binding inhibitor and total cholesterol plasma levels in cirrhosis and hepatocellular carcinoma. *Regul. Pept.* **1998**, *74*, 31-34. [CrossRef] [PubMed]

368. Atak, A.; Khurana, S.; Gollapalli, K.; Reddy, P.J.; Levy, R.; Ben-Salmon, S.; Hollander, D.; Donyo, M.; Heit, A.; Hotz-Wagenblatt, A.; et al. Quantitative mass spectrometry analysis reveals a panel of nine proteins as diagnostic markers for colon adenocarcinomas. *Oncotarget* **2018**, *9*, 13530-13544. [CrossRef]

369. Gossett, R.E.; Schroeder, F.; Gunn, J.M.; Kier, A.B. Expression of fatty acyl-coa binding proteins in colon cells: Response to butyrate and transformation. *Lipids* **1997**, *32*, 577-585. [CrossRef] [PubMed]

370. Fijan, S. Microorganisms with claimed probiotic properties: An overview of recent literature. *Int. J. Environ. Res. Public Health* **2014**, *11*, 4745-4767. [CrossRef] [PubMed]

371. Czerucka, D.; Piche, T.; Rampal, P. Review article: Yeast as probiotics—Saccharomyces boulardii. *Aliment. Pharmacol. Ther.* **2007**, *26*, 767-778. [CrossRef]

372. Chang, C.J.; Lin, T.L.; Tsai, Y.L.; Wu, T.R.; Lai, W.F.; Lu, C.C.; Lai, H.C. Next generation probiotics in disease amelioration. *J. Food Drug Anal.* **2019**, *27*, 615-622. [CrossRef] [PubMed]

373. Seo, M.J.; Won, S.M.; Kwon, M.J.; Song, J.H.; Lee, E.B.; Cho, J.H.; Park, K.W.; Yoon, J.H. Screening of lactic acid bacteria with anti-adipogenic effect and potential probiotic properties from grains. *Sci. Rep.* **2023**, *13*, 11022. [CrossRef] [PubMed]

374. Hatakka, K.; Holma, R.; El-Nezami, H.; Suomalainen, T.; Kuisma, M.; Saxelin, M.; Poussa, T.; Mykkanen, H.; Korpela, R. The influence of lactobacillus rhamnosus Ic705 together with propionibacterium freudenreichii ssp. Shermanii js on potentially carcinogenic bacterial activity in human colon. *Int. J. Food Microbiol.* **2008**, *128*, 406-410. [CrossRef] [PubMed]

375. Salminen, S.; Collado, M.C.; Endo, A.; Hill, C.; Lebeer, S.; Quigley, E.M.M.; Sanders, M.E.; Shamir, R.; Swann, J.R.; Szajewska, H.; et al. The international scientific association of probiotics and prebiotics (isapp) consensus statement on the definition and scope of postbiotics. *Nat. Rev. Gastroenterol. Hepatol.* **2021**, *18*, 649-667. [CrossRef] [PubMed]

376. Qamar, T.R.; Iqbal, S.; Syed, F.; Nasir, M.; Rehman, H.; Iqbal, M.A.; Liu, R.H. Impact of novel prebiotic galacto-oligosaccharides on various biomarkers of colorectal cancer in wister rats. *Int. J. Mol. Sci.* **2017**, *18*, 1785. [CrossRef] [PubMed]
377. Qamar, T.R.; Syed, F.; Nasir, M.; Rehman, H.; Zahid, M.N.; Liu, R.H.; Iqbal, S. Novel combination of prebiotics galacto-oligosaccharides and inulin-inhibited aberrant crypt foci formation and biomarkers of colon cancer in wistar rats. *Nutrients* **2016**, *8*, 465. [CrossRef]

378. Kim, C.E.; Yoon, L.S.; Michels, K.B.; Tranfield, W.; Jacobs, J.P.; May, F.P. The impact of prebiotic, probiotic, and synbiotic supplements and yogurt consumption on the risk of colorectal neoplasia among adults: A systematic review. *Nutrients* **2022**, *14*, 4937. [CrossRef]

379. Senesse, P.; Boutron-Ruault, M.C.; Faivre, J.; Chatelain, N.; Belghiti, C.; Meance, S. Foods as risk factors for colorectal adenomas: A case-control study in burgundy (france). *Nutr. Cancer* **2002**, *44*, 7–15. [CrossRef] [PubMed]

380. Michels, K.B.; Willett, W.C.; Vaidya, R.; Zhang, X.; Giovannucci, E. Yogurt consumption and colorectal cancer incidence and mortality in the nurses’ health study and the health professionals follow-up study. *Am. J. Clin. Nutr.* **2020**, *112*, 1566–1575. [CrossRef] [PubMed]

381. Pala, V.; Sieri, S.; Berrino, F.; Vineis, P.; Sacerdote, C.; Palli, D.; Masala, G.; Panico, S.; Mattiello, A.; Tumino, R.; et al. Yogurt consumption and risk of colorectal cancer in the italian european prospective investigation into cancer and nutrition cohort. *Int. J. Cancer* **2011**, *129*, 2712–2719. [CrossRef] [PubMed]

382. Murphy, N.; Norat, T.; Ferrari, P.; Jenab, M.; Bueno-de-Mesquita, B.; Skeie, G.; Olsen, A.; Tjonneland, A.; Dahm, C.C.; Overvad, K.; et al. Consumption of dairy products and colorectal cancer in the european prospective investigation into cancer and nutrition (epic). *PLoS ONE* **2013**, *8*, e72715. [CrossRef] [PubMed]

383. Le Leu, R.K.; Brown, I.L.; Hu, Y.; Bird, A.R.; Jackson, M.; Esterman, A.; Young, G.P. A synbiotic combination of resistant starch and bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. *J. Nutr.* **2005**, *135*, 996–1001. [CrossRef] [PubMed]

384. Le Leu, R.K.; Hu, Y.; Brown, I.L.; Woodman, R.J.; Young, G.P. Synbiotic intervention of bifidobacterium lactis and resistant starch protects against colorectal cancer development in rats. *Carcinogenesis* **2010**, *31*, 246–251. [CrossRef] [PubMed]

385. Femia, A.P.; Luceri, C.; Dolara, P.; Giannini, A.; Biggeri, A.; Salvadori, M.; Clune, Y.; Collins, K.J.; Paglierani, M.; Caderni, G. Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics lactobacillus rhamnosus and bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats. *Carcinogenesis* **2002**, *23*, 1953–1960. [CrossRef] [PubMed]

386. Rafter, J.; Bennett, M.; Caderni, G.; Clune, Y.; Hughes, R.; Karlsson, P.C.; Klinder, A.; O’Riordan, M.; O’Sullivan, G.C.; Pool-Zobel, B.; et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am. J. Clin. Nutr.* **2007**, *85*, 488–496. [CrossRef]

387. Fratila, T.D.; Ismaiel, A.; Dumitrascu, D.L. Microbiome modulation in the prevention and management of colorectal cancer: A systematic review of clinical interventions. *Med. Pharm. Rep.* **2023**, *96*, 131–145. [CrossRef]

388. Xu, M.Q.; Cao, H.L.; Wang, W.Q.; Wang, S.; Cao, X.C.; Yan, F.; Wang, B.M. Fecal microbiota transplantation broadening its application beyond intestinal disorders. *World J. Gastroenterol.* **2015**, *21*, 102–111. [CrossRef]

389. Lang, T.; Zhu, R.; Zhu, X.; Yan, W.; Li, Y.; Zhai, Y.; Wu, T.; Huang, X.; Yin, Q.; Li, Y. Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy. *Nat. Commun.* **2023**, *14*, 4746. [CrossRef] [PubMed]

390. Xu, Q.; Gao, J.; Zhao, R.; Li, H.; Cui, H.; Yuan, Z.; Ren, H.; Cao, B.; Wei, B. Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis. *Pharmacol. Res.* **2024**, *206*, 107278. [CrossRef] [PubMed]

391. Jia, Z.H.; Wang, X.G.; Zhang, H. Overcome cancer drug resistance by targeting epigenetic modifications of centrosome. *Cancer Drug Resist.* **2019**, *2*, 210–224. [CrossRef] [PubMed]

392. Raynal, N.J.; Da Costa, E.M.; Lee, J.T.; Gharibyan, V.; Ahmed, S.; Zhang, H.; Sato, T.; Malouf, G.G.; Issa, J.J. Repositioning fda-approved drugs in combination with epigenetic drugs to reprogram colon cancer epigenome. *Mol. Cancer Ther.* **2017**, *16*, 397–407. [CrossRef]

393. Sharma, A.; Vatapalli, R.; Abdelfatah, E.; Wyatt McMahon, K.; Kerner, Z.; Guzzetta, A.A.; Singh, J.; Zahnow, C.; Baylin, S.B.; Yerram, S.; et al. Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells. *PLoS ONE* **2017**, *12*, e0176139. [CrossRef] [PubMed]

394. Flis, S.; Gnyszka, A.; Flis, K. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in sw48 and ht-29 colorectal cancer cells. *PLoS ONE* **2014**, *9*, e92305. [CrossRef] [PubMed]

395. Huang, K.C.; Ke, T.W.; Lai, C.Y.; Hong, W.Z.; Chang, H.Y.; Lee, C.Y.; Wu, C.H.; Chiang, S.F.; Liang, J.A.; Chen, J.Y.; et al. Inhibition of dnmts increases neoantigen-reactive t-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy. *Biomed. Pharmacother. Biomed. Pharmacother.* **2024**, *177*, 116958. [CrossRef] [PubMed]

396. Huang, K.C.; Chiang, S.F.; Ke, T.W.; Chen, T.W.; Hu, C.H.; Yang, P.C.; Chang, H.Y.; Liang, J.A.; Chen, W.T.; Chao, K.S.C. Dnmt1 constrains ifnbeta-mediated anti-tumor immunity and pd-l1 expression to reduce the efficacy of radiotherapy and immunotherapy. *Oncoimmunology* **2021**, *10*, 1989790. [CrossRef] [PubMed]

397. Wang, F.; Jin, Y.; Wang, M.; Luo, H.Y.; Fang, W.J.; Wang, Y.N.; Chen, Y.X.; Huang, R.J.; Guan, W.L.; Li, J.B.; et al. Combined anti-pd-1, hdac inhibitor and anti-vegf for mss/pmmr colorectal cancer: A randomized phase 2 trial. *Nat. Med.* **2024**, *30*, 1035–1043. [CrossRef]
398. Liang, X.L.; Ouyang, L.; Yu, N.N.; Sun, Z.H.; Gui, Z.K.; Niu, Y.L.; He, Q.Y.; Zhang, J.; Wang, Y. Histone deacetylase inhibitor pracinostat suppresses colorectal cancer by inducing cdk5-drp1 signaling-mediated peripheral mitofission. *J. Pharm. Anal.* **2023**, *13*, 1168–1182. [CrossRef]

399. D'Angelo, S.; Motti, M.L.; Meccariello, R. Omega-3 and omega-6 polyunsaturated fatty acids, obesity and cancer. *Nutrients* **2020**, *12*, 2751. [CrossRef] [PubMed]

400. Cholewski, M.; Tomczykowa, M.; Tomczyk, M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. *Nutrients* **2018**, *10*, 1662. [CrossRef] [PubMed]

401. Flachs, P.; Rossmeisl, M.; Bryhn, M.; Kopecky, J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. *Clin. Sci.* **2009**, *116*, 1–16. [CrossRef] [PubMed]

402. Kalupahana, N.S.; Claycombe, K.J.; Moustaid-Moussa, N. (n-3) fatty acids alleviate adipose tissue inflammation and insulin resistance: Mechanistic insights. *Adv. Nutr.* **2011**, *2*, 304–316. [CrossRef] [PubMed]

403. Howard, B.V.; Van Horn, L.; Hsia, J.; Manson, J.E.; Stefanick, M.L.; Wassertheil-Smoller, S.; Kuller, L.H.; LaCroix, A.Z.; Langer, R.D.; Lasser, N.L.; et al. Low-fat dietary pattern and risk of cardiovascular disease: The women's health initiative randomized controlled dietary modification trial. *JAMA* **2006**, *295*, 655–666. [CrossRef] [PubMed]

404. Agnoli, C.; Grioni, S.; Sieri, S.; Palli, D.; Masala, G.; Sacerdote, C.; Vineis, P.; Tumino, R.; Giurdanella, M.C.; Pala, V.; et al. Italian mediterranean index and risk of colorectal cancer in the italian section of the epic cohort. *Int. J. Cancer* **2013**, *132*, 1404–1411. [CrossRef] [PubMed]

405. Jones, P.; Cade, J.E.; Evans, C.E.L.; Hancock, N.; Greenwood, D.C. The mediterranean diet and risk of colorectal cancer in the uk women's cohort study. *Int. J. Epidemiol.* **2017**, *46*, 1786–1796. [CrossRef] [PubMed]

406. Jafari Nasab, S.; Clark, C.C.T.; Entezari, M. Mediterranean diet and colorectal adenomas: A systematic review and meta-analysis of observational studies. *Eur. J. Cancer Prev. Off. J. Eur. Cancer Prev. Organ.* **2024**, *33*, 223–231. [CrossRef] [PubMed]

407. Algamas-Dimantov, A.; Yehuda-Shnaidman, E.; Hertz, R.; Peri, I.; Bar-Tana, J.; Schwartz, B. Prevention of diabetes-promoted colorectal cancer by (n-3) polyunsaturated fatty acids and (n-3) pufa mimetic. *Oncotarget* **2014**, *5*, 9851–9863. [CrossRef]

408. Molendi-Coste, O.; Legry, V.; Leclercq, I.A. Why and how meet n-3 pufa dietary recommendations? *Gastroenterol. Res. Pract.* **2011**, *11*, 364040. [CrossRef]

409. Eaton, S.B.; Konner, M.J.; Cordain, L. Diet-dependent acid load, paleolithic [corrected] nutrition, and evolutionary health promotion. *Am. J. Clin. Nutr.* **2010**, *91*, 295–297. [CrossRef] [PubMed]

410. Shehzad, A.; Khan, S.; Sup Lee, Y. Curcumin molecular targets in obesity and obesity-related cancers. *Future Oncol.* **2012**, *8*, 179–190. [CrossRef]

411. Johnson, S.M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B.M. Curcumin inhibits proliferation of colorectal carcinoma by modulating akt/mtor signaling. *Anticancer Res.* **2009**, *29*, 3185–3190.

412. Dou, H.; Shen, R.; Tao, J.; Huang, L.; Shi, H.; Chen, H.; Wang, Y.; Wang, T. Curcumin suppresses the colon cancer proliferation by inhibiting wnt/beta-catenin pathways via mir-130a. *Front. Pharmacol.* **2017**, *8*, 877. [CrossRef]

413. Johnson, J.J.; Mukhtar, H. Curcumin for chemoprevention of colon cancer. *Cancer Lett.* **2007**, *255*, 170–181. [CrossRef] [PubMed]

414. Wu, X.; Pfalzer, A.C.; Koh, G.Y.; Tang, S.; Crott, J.W.; Thomas, M.J.; Meydani, M.; Mason, J.B. Curcumin and salsalate suppresses colonic inflammation and procarcinogenic signaling in high-fat-fed, azoxymethane-treated mice. *J. Agric. Food Chem.* **2017**, *65*, 7200–7209. [CrossRef]

415. Wu, X.; Koh, G.Y.; Huang, Y.; Crott, J.W.; Bronson, R.T.; Mason, J.B. The combination of curcumin and salsalate is superior to either agent alone in suppressing pro-cancerous molecular pathways and colorectal tumorigenesis in obese mice. *Mol. Nutr. Food Res.* **2019**, *63*, e1801097. [CrossRef]

416. Carroll, R.E.; Benya, R.V.; Turgeon, D.K.; Vareed, S.; Neuman, M.; Rodriguez, L.; Kakarala, M.; Carpenter, P.M.; McLaren, C.; Meyskens, F.L., Jr.; et al. Phase IIA clinical trial of curcumin for the prevention of colorectal neoplasia. *Cancer Prev. Res.* **2011**, *4*, 354–364. [CrossRef]

417. Moetlediwa, M.T.; Ramashia, R.; Pheiffer, C.; Titinchi, S.J.J.; Mazibuko-Mbeje, S.E.; Jack, B.U. Therapeutic effects of curcumin derivatives against obesity and associated metabolic complications: A review of in vitro and in vivo studies. *Int. J. Mol. Sci.* **2023**, *24*, 14366. [CrossRef] [PubMed]

418. Vanamala, J.; Reddivari, L.; Radhakrishnan, S.; Tarver, C. Resveratrol suppresses igf-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of igf-1r/wnt and activation of p53 signaling pathways. *BMC Cancer* **2010**, *10*, 238. [CrossRef]

419. Vanamala, J.; Radhakrishnan, S.; Reddivari, L.; Bhat, V.B.; Ptitsyn, A. Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-fak signaling pathways-a proteomic approach. *Proteome Sci.* **2011**, *9*, 49. [CrossRef] [PubMed]

420. Ji, Q.; Liu, X.; Fu, X.; Zhang, L.; Sui, H.; Zhou, L.; Sun, J.; Cai, J.; Qin, J.; Ren, J.; et al. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via malat1 mediated wnt/beta-catenin signal pathway. *PLoS ONE* **2013**, *8*, e78700. [CrossRef] [PubMed]

421. Shimizu, M.; Shirakami, Y.; Sakai, H.; Adachi, S.; Hata, K.; Hirose, Y.; Tsurumi, H.; Tanaka, T.; Moriwaki, H. (-)-epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male c57bl/ksj-db/db mice. *Cancer Prev. Res.* **2008**, *1*, 298–304. [CrossRef] [PubMed]

422. Huang, J.; Wang, Y.; Xie, Z.; Zhou, Y.; Zhang, Y.; Wan, X. The anti-obesity effects of green tea in human intervention and basic molecular studies. *Eur. J. Clin. Nutr.* **2014**, *68*, 1075–1087. [CrossRef] [PubMed]
423. Saldanha, S.N.; Kala, R.; Tollefsbol, T.O. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. *Exp. Cell Res.* **2014**, *324*, 40–53. [CrossRef] [PubMed]

424. Kwon, O.S.; Jung, J.H.; Shin, E.A.; Park, J.E.; Park, W.Y.; Kim, S.H. Epigallocatechin-3-gallate induces apoptosis as a trail sensitizer via activation of caspase 8 and death receptor 5 in human colon cancer cells. *Biomedicines* **2020**, *8*, 84. [CrossRef] [PubMed]

425. Miyamoto, S.; Yasui, Y.; Ohigashi, H.; Tanaka, T.; Murakami, A. Dietary flavonoids suppress azoxymethane-induced colonic preneoplastic lesions in male c57bl/ksj-db/db mice. *Chem.-Biol. Interact.* **2010**, *183*, 276–283. [CrossRef]

426. Benito, I.; Encio, I.J.; Milagro, F.I.; Alfaro, M.; Martinez-Penuela, A.; Barajas, M.; Marzo, F. Microencapsulated bifidobacterium bifidum and lactobacillus gasseri in combination with quercetin inhibit colorectal cancer development in apc(min/+) mice. *Int. J. Mol. Sci.* **2021**, *22*, 4906. [CrossRef]

427. Fike, L.T.; Munro, H.; Yu, D.; Dai, Q.; Shrubsole, M.J. Dietary polyphenols and the risk of colorectal cancer in the prospective southern community cohort study. *Am. J. Clin. Nutr.* **2022**, *115*, 1155–1165. [CrossRef]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.